Concepedia

Author

Antonio Cusmai

Istituto Tumori BariORCID

Also Known As

A CUSMAI, A Cusmai, A. Cusmai, Antonio Cusmai

42

Publications

964

Citations

14

H-Index

18

Concepts

All Affiliations

Istituto Tumori BariUniversity of Bari Aldo MoroFondazione IRCCS Istituto Nazionale dei TumoriUniversity of Modena and Reggio EmiliaIstituti di Ricovero e Cura a Carattere Scientifico
AC

About

Antonio Cusmai is an author at Istituto Tumori Bari specializing in medicine, radiation oncology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

109

2

Health Sciences

1

1

83

3

Cell Biology

1

1

83

4

Immunology

1

1

83

5

Pharmacology

1

1

12

Antonio Cusmai

×

8

Publications

449

Citations

8

H-Index

YearCitations

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

Maria Antonia Frassanito, Antonio Cusmai, Giuseppe Iodice,

Blood

2001

158

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?

Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola,

Expert Review of Gastroenterology & Hepatology

2022

87

Deregulated cytokine network and defective Th1 immune response in multiple myeloma

Maria Antonia Frassanito, Antonio Cusmai, Franco Dammacco

Clinical & Experimental Immunology

2001

83

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Mélanie Claps, Chiara Pircher,

Tumori Journal

2022

46

Manumycin inhibits farnesyltransferase and induces apoptosis of drug‐resistant interleukin 6‐producing myeloma cells

Maria Antonia Frassanito, Antonio Cusmai, Cláudia Piccoli,

British Journal of Haematology

2002

32

Combined cyclosporin-A /prednisone therapy of patients with active uveitis suppresses IFN-<i>γ</i> production and the function of dendritic cells

M A Frassanito, Rosanna Dammacco, Trevor Fusaro,

Clinical & Experimental Immunology

2003

17

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

Umberto Basso, Federico Paolieri, Mimma Rizzo,

Cancers

2022

14

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

Mariangela Ciccarese, Alessandra Fabi, Luca Moscetti,

Breast Cancer Research and Treatment

2017

12

Page 1